Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease in Adults The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Areas of Ongoing Research and Debate: GIPs Effects on Weight: While GLP-1's effects on weight are well-recognized, the exact role of GIP in body weight regulation is less clear
Keep the needle in place for at least 6 seconds to ensure the full dose is delivered
These studies have focused on Glutathione's antioxidant and anti-inflammatory properties, which may help alleviate the symptoms associated with these conditions
Immunizations: common vaccinations such as flu shots, Tdap, and HPV
